Genetic diagnosis of familial hypercholesterolemia in affected relatives using pedigree tracing

Clinical Biochemistry

Volumn 29, Issue 4, 1996, Pages 371-377

  Hsia, Stanley H ^a   Connelly, Philip W ^a   Hegele, Robert A ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

familial hypercholesterolemia; founder effect; LDL receptor; molecular genetics

Indexed keywords

CHOLESTEROL; CYSTEINE; DNA; ENDONUCLEASE; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADULT; ARTICLE; CASE REPORT; FAMILIAL HYPERCHOLESTEROLEMIA; HETEROZYGOTE; HUMAN; MALE; MUTATION; PEDIGREE ANALYSIS; PRIORITY JOURNAL; RELATIVE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 0029996916     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/0009-9120(96)00017-3     Document Type: Article

References (57)

1. 1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York, NY: McGraw Hill; 1995: 1981-2030.
2. 2. Hobbs HH, Brown MS, Russell DW, Davignon J, Goldstein JL. Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N Engl J Med 1987; 317: 734-7.
3. 3. Moorjani S, Roy M, Gagné C, Davignon J, Brun D, Toussaint M, Lambert M, Campeau L, Blaichman S, Lupien P. Homozygous familial hypercholesterolemia among French Canadians in Québec province. Arteriosclerosis 1989; 9: 211-6.
4. 4. Ma Y, Bétard C, Roy M, Davignon J, Kessling AM. Identification of a second "French Canadian" LDL receptor gene deletion and development of a rapid method to detect both deletions. Clin Genet 1989; 36: 219-28.
5. 5. Seftel HC, Baker SG, Sandler MP, Forman MB, Joffe BI, Mendelsohn D, Jenkins T, Mieny CJ. A host of hypercholesterolaemic homozygotes in South Africa. Br Med J 1980; 281: 633-6.
6. 6. Aalto-Setälä K, Helve E, Kovanen PT, Kontula K. Finnish type of low density lipoprotein receptor gene mutation (FH-Helsinki) deletes exons encoding the carboxy-terminal part of the receptor and creates an internalization-defective phenotype. J Clin Invest 1989; 84: 499-505.
7. 7. Meiner V, Landsberger D, Berkman N, Reshef A, Segal P, Seftel HC, van der Westhuyzen DR, Jeenah MS, Coetzee GA, Leitersdorf E. A common Lithuanian mutation causing familial hypercholesterolemia in Ashkenazi Jews. Am J Hum Genet 1991; 49: 443-9.
8. 8. Khachadurian AK, Uthman SM. Experiences with the homozygous cases of familial hypercholesterolemia. Nutr Metabol 1973; 15: 132-40.
9. 9. Oppenheim A, Friedlander Y, Dann EJ, Berkman N, Pressman Schwartz S, Leitersdorf E. Hypercholesterolemia in five Israeli Christian-Arab kindreds is caused by the "Lebanese" allele at the low density lipoprotein receptor gene locus and by an additional independent major factor. Hum Genet 1991; 88: 75-84.
10. 10. Bétard C, Kessling AM, Roy M, Chamberland A, Lussier-Cacan S, Davignon J. Molecular genetic evidence for a founder effect in familial hypercholesterolemia among French Canadians. Hum Genet 1992; 88: 529-36.
11. 11. Brown MS, Goldstein JL. Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc Natl Acad Sci USA 1974; 71: 788-92.
12. 12. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
13. 13. Francke U, Brown MS, Goldstein JL. Assignment of the human gene for the low density lipoprotein receptor to chromosome 19: synteny of a receptor, a ligand and a genetic disease. Proc Natl Acad Sci USA 1984; 81: 2826-30.
14. 14. Myant NB. The LDL receptor: structure, biosynthesis, and molecular genetics. In: Cholesterol Metabolism, LDL, and the LDL Receptor, San Diego, CA: Academic Press; 1990: 316-96.
15. 15. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Human Mutation 1992; 1: 445-66.
16. 16. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Ann Rev Genet 1990; 24: 133-70.
17. 17. Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J, McCarthy BJ. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 1990; 31: 1337-49.
18. 18. Tybjaerg-Hansen A, Gallagher J, Vincent J, Houlston R, Talmud P, Dunning AM, Seed M, Hamsten A, Humphries SE, Myant NB. Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases. Atherosclerosis 1990; 80: 235-42.
19. 19. Davignon J, Dufour R, Roy M, Bétard C, Ma Y, Ouellette S, Boulet L, Lussier-Cacan S. Phenotypic heterogeneity associated with defective apolipoprotein B-100 and occurrence of the familial hypercholesterolemia phenotype in the absence of an LDL-receptor defect within a Canadian kindred. Eur J Epidemiol 1992; 8suppl 1: 10-7.
20. 20. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986; 314: 488-500.
21. 21. The Canadian Consensus Conference on Cholesterol. Final Report: The Canadian Consensus Conference on the prevention of heart and vascular disease by altering serum cholesterol and lipoprotein risk factors. Can Med Assoc J 1988; 139(11)suppl: 1-8.
22. 22. The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64.
23. 23. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA. Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45.
24. 24. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-40.
25. 25. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98.
26. 26. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
27. 27. Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: a look back and a look ahead. Can J Cardiol 1992; 8: 843-64.
28. 28. Pearson TA. Diagnosis and case finding in familial hypercholesterolemia. Am J Cardiol 1993; 72: 15D-17D.
29. 29. Williams RR, Schumacher MC, Barlow GK, Hunt SC, Ware JL, Pratt M, Latham BD. Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah. Am J Cardiol 1993; 72: 18D-24D.
30. 30. Goldman L, Goldman PA, Williams LW, Weinstein MC. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am J Cardiol 1993; 72: 75D-79D.
31. 31. Lehrman MA, Schneider WJ, Brown MS, Davis CG, Elhammer A, Russell DW, Goldstein JL. The Lebanese allele at the low density lipoprotein receptor locus. J Biol Chem 1987; 262: 401-10.
32. 32. Reshef A, Meiner V, Dann EJ, Granat M, Leitersdorf E. Prenatal diagnosis of familial hypercholesterolemia caused by the "Lebanese" mutation at the low density lipoprotein receptor locus. Hum Genet 1992; 89: 237-9.
33. 33. Walden CC, Huff MW, Leiter LA, Connelly PW, Hegele RA. Detection of a new apolipoprotein-E mutation in type III hyperlipidemia using deoxyribonucleic acid restriction isotyping. J Clin Endocrinol Metab 1994; 78: 699-704.
34. 34. Figueiredo MS, Dos Santos JE, Alberto FL, Zago MA. High frequency of the Lebanese allele of the LDLr gene among Brazilian patients with familial hypercholesterolemia. J Med Genet 1992; 29: 813-5.
35. 35. Leitersdorf E, Tobin EJ, Davignon J, Hobbs HH. Common low-density lipoprotein receptor mutations in the French Canadian population. J Clin Invest 1990; 85: 1014-23.
36. 36. Moorjani S, Roy M, Torres A, Bétard C, Gagné C, Lambert M, Brun D, Davignon J, Lupien P. Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolemia. Lancet 1993; 341: 1303-6.
37. 37. Hill JS, Hayden MR, Frohlich J, Pritchard PH. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb 1991; 11: 290-7.
38. 38. Rose V, Wilson G, Steiner G. Familial hypercholesterolemia: report of coronary death at age 3 in a homozygous child and prenatal diagnosis in a heterozygous sibling. J Pediatr 1982; 100: 757-9.
39. 3 deficiency: report of two cases. Arteriosclerosis 1984; 4: 124-9.
40. 40. Dallongeville J, Roy M, Leboeuf N, Xhignesse M, Davignon J, Lussier-Cacan S. Apolipoprotein E polymorphism association with lipoprotein profile in endogenous hypertriglyceridemia and familial hypercholesterolemia. Arterioscler Thromb 1991; 11: 272-8.
41. 41. Utermann G. Apolipoprotein E polymorphism in health and disease. Am Heart J 1987; 113: 433-40.
42. 42. Carmena R, Roederer G, Mailloux H, Lussier-Cacan S, Davignon J. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism 1993; 42: 895-901.
43. 43. Soutar AK, Myant NB, Thompson GR. The metabolism of very low density and intermediate density lipoproteins in patients with familial hypercholesterolemia. Atherosclerosis 1982; 43: 217-31.
44. 44. Streja D, Steiner G, Kwiterovich PO. Plasma high-density lipoproteins and ischemic heart disease: studies in a large kindred with familial hypercholesterolemia. Ann Int Med 1978; 89: 871-80.
45. 45. Schaefer JR, Rader DJ, Ikewaki K, Fairwell T, Zech LA, Kindt MR, Davignon J, Gregg RE, Brewer HB Jr. In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia. Arterioscler Thromb 1992; 12: 843-8.
46. 46. Mahley RW, Innerarity TL, Weisgraber KH, Oh SY. Altered metabolism (in vivo and in vitro) of plasma lipoproteins after selective chemical modification of lysine residues of the apoproteins. J Clin Invest 1979; 64: 743-50.
47. 47. Mbewu AD, Bhatnagar D, Durrington PN, Hunt L, Ishola M, Arrol S, Mackness M, Lockley P, Miller JP. Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives and unrelated control populations. Arterioscler Thromb 1991; 11: 940-6.
48. 48. Utermann G, Hoppichler F, Dieplinger H, Seed H, Thompson G, Boerwinkle E. Defects in the low density lipoprotein receptor gene affect lipoprotein(a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci USA 1989; 86: 4171-4.
49. 49. Hegele RA, Sutherland S, Robertson M, Wu LL, Emi M, Hopkins PN, Williams RR, Lalouel JM. The effect of genetic determinants of low density lipoprotein levels on lipoprotein (a). Clin Invest Med 1991; 14: 146-52.
50. 664-Leu mutation in the low-density lipoprotein receptor and its relation to lipoprotein(a) levels in patients with familial hypercholesterolemia of Dutch ancestry from The Netherlands and Canada. Clin Genet 1992; 42: 273-80.
51. 51. Hegele RA, Connelly PW, Cullen-Dean G, Rose V. Elevated plasma lipoprotein(a) associated with abnormal stress thallium scans in children with familial hypercholesterolemia. Am J Cardiol 1993; 72: 402-6.
52. 52. Zambon A, Torres A, Bijvoet S, Gagné C, Moorjani S, Lupien PJ, Hayden MR, Brunzell JD. Prevention of raised low-density lipoprotein cholesterol in a patient with familial hypercholesterolemia and lipoprotein lipase deficiency. Lancet 1993; 341: 1119-21.
53. 53. Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, Hopkins PN. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72: 171-6.
54. 54. Hegele RA, Emi M, Wu LL, Hopkins PN, Williams RR, Lalouel J-M. Clinical application of deoxyribonucleic acid markers in a Utah family with hypercholesterolemia. Am J Cardiol 1989; 63: 109-12.
55. 55. Karayan L, Qiu S, Bétard C, Dufour R, Roederer G, Minnich A, Davignon J, Genest J Jr. Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ("French Canadian mutation") of the LDL receptor gene. Arterioscler Thromb 1994; 14: 1258-63.
56. 56. Jeenah M, September W, Graadt van Roggen F, de Villiers W, Seftel H, Marais D. Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1993; 98: 51-8.
57. 57. Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N, Dann EJ, Landsberger D, Sehayek E, Meiner V, Wurm M, Bard J-M, Fruchart J-C, Stein Y. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation 1993; 87(suppl III): III-35-44.